Hjem › Osteosarkom › North Carolina
Osteosarkom kliniske forsøg i North Carolina
6 studier for Osteosarkom søger deltagere på steder i North Carolina.
Byer i North Carolina
Officiel studietekst (engelsk)
Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor
- Duke University Medical Center, Durham
RekruttererFase 2
Alder 12 til 39 · Alle køn · Opdateret 29. sep. 2026 · NCT04616560The CATSINDO Trial - Clinical and Translational Study in Newly Diagnosed Osteosarcoma
- University of North Carolina at Chapel Hill, Chapel Hill
- Atrium Health Levine Children's Hospital, Charlotte
- Novant Health Hemby Children's Hospital, Charlotte
- og 3 flere
RekruttererFase 2
Alder 7 til 22 · Alle køn · Opdateret 25. sep. 2026 · NCT07560826Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
- Mission Hospital, Asheville
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Duke University Medical Center, Durham
- og 2 flere
RekruttererFase 3
Op til 50 år · Alle køn · Opdateret 25. aug. 2026 · NCT05235165SPEARHEAD-3 Pediatric Study
- Duke University School of Medicine, Durham
RekruttererFase 1/2
Alder 2 til 21 · Alle køn · Opdateret 11. aug. 2026 · NCT05642455Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- Mission Hospital, Asheville
- Wake Forest University Health Sciences, Winston-Salem
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 18. maj 2026 · NCT01790152Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
RekruttererFase 1
18 Months · Alle køn · Opdateret 27. mar. 2026 · NCT03721068Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.